Target Validation Information
TTD ID	T24793
Target Name	Voltage-gated calcium channel alpha Cav1.3 (CACNA1D)
Type of Target	Clinical trial
Drug Potency against Target	ARC029	Drug Info	IC50 = 1.04 nM	[2]
	CGS-27830	Drug Info	IC50 = 592 nM
	CV-4093	Drug Info	IC50 = 8.68 nM	[2]
	N,N'-Di-acenaphthen-5-yl-guanidine	Drug Info	IC50 = 1130 nM
	PD-32577	Drug Info	IC50 = 2000 nM	[1]
	SIPATRIGINE	Drug Info	IC50 = 3860 nM
	SNAP-5089	Drug Info	Ki = 540 nM	[3]
References
REF 1	Synthesis and biological activity of substituted bis-(4-hydroxyphenyl)methanes as N-type calcium channel blockers. Bioorg Med Chem Lett. 1999 Aug 16;9(16):2447-52.
REF 2	Dihydropyrimidines: novel calcium antagonists with potent and long-lasting vasodilative and antihypertensive activity. J Med Chem. 1989 Oct;32(10):2399-406.
REF 3	Discovery of alpha 1a-adrenergic receptor antagonists based on the L-type Ca2+ channel antagonist niguldipine. J Med Chem. 1995 May 12;38(10):1579-81.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.